Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/10/2026

1. SKHY
2. META
3. PEP
4. USO
5. SPY
6. DAL
7. WRAP
8. CRCL
9. KBH
10. IONS

Go back to Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
(NASDAQ: PCVX) Delayed: 57.53 -2.3 (3.84%)
Previous Close $59.83    52 Week High $ 
Open $59.87    52 Week Low $ 
Day High $59.91    P/E N/A 
Day Low $56.65    EPS $ 
Volume 201,900